je.st
news
Results of Phase II PRECEDENT Trial for Investigational Folate Receptor Therapy Vintafolide in Patients with Platinum-Resistant Ovarian Cancer Published in Journal of Clinical Oncology
2013-10-14 23:02:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind. Merck and Endocytes Phase III PROCEED pivotal trial of vintafolide in ovarian cancer ongoing WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology. Language: English Contact: MerckMedia:Caroline Lappetito,267-305-7639Caroline.Lappetito@Merck.comorClaire Mulhearn, 908-423-7425Claire.Mulhearn@Merck.comorInvestors:Carol Ferguson, 908-423-4465Carol.Ferguson@Merck.comorJustin Holko, 908-423-5088Justin_Holko@Merck.comorEndocyteMedia:Tony Russo, 212-845-4251Tony.Russo@Russopartnersllc.comorMartina Schwarzkopf, 212-845-4292Martina.Schwarzkopf@Russopartnersllc.comorInvestors:Stephanie Ascher, 212-362-1200Stephanie@sternir.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: ECYT Exchange: NASDAQ read more
Tags: of
results
journal
published
Category:Biotechnology and Pharmaceuticals